Cited by 990Immune cells in cancerCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Dynamics of the immune reaction to pancreatic cancer from inception to invasion

Open access
Clark, Carolyn E., Hingorani, Sunil R., Mick, Rosemarie, Combs, Chelsea, Tuveson, David A., Vonderheide, Robert H.·2007·Cancer Research

Published version of a preprint

Abstract

The dynamics of cancer immunosurveillance remain incompletely understood, hampering efforts to develop immunotherapy of cancer. We evaluated the evolving in vivo immune response to a spontaneous tumor in a genetically defined mouse model of pancreatic ductal adenocarcinoma from the inception of preinvasive disease to invasive cancer. We observed a prominent leukocytic infiltration even around the lowest grade preinvasive lesions, but immunosuppressive cells, including tumor-associated macrophages, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg), dominated the early response and persisted through invasive cancer. Effector T cells, however, were scarce in preinvasive lesions, found in only a subset of advanced cancers, and showed no evidence of activation. The lack of tumor-infiltrating effector T cells strongly correlated with the presence of intratumoral MDSC with a near mutual exclusion. In vitro, we found that MDSC suppressed T-cell proliferation. Overall, our results show that suppressive cells of the host immune system appear early during pancreatic tumorigenesis, preceding and outweighing antitumor cellular immunity, and likely contribute to disease progression. Thus, in contrast to the hypothesis that an early “elimination phase” of cancer immunosurveillance is eventually overwhelmed by a growing invasive tumor, our findings suggest that productive tumor immunity may be undermined from the start. Efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer. [Cancer Res 2007;67(19):9518–27]

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-0175

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The PDAC TME features abundant immune-suppressive myeloid cells and regulatory T cells and scarce cytotoxic lymphocytes.

    “The PDAC TME features abundant immune-suppressive myeloid cells and regulatory T cells (T reg cells) and scarce cytotoxic lymphocytes (Clark et al., 2007; Vonderheide and Bayne, 2013).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Burnet F. Cancer-a biological approach. Br Med J 1957; 1:841-7.
  2. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77: 1303-10.
  3. Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-h as prognostic factors in breast carcinoma. Int J Cancer 1997;74:492-501.

Cited by

Sorted by citations

Authors
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H.
Affiliations
  • Abramson Cancer Center (US)
  • University of Washington (US)
  • University of Pennsylvania (US)
Venue
Cancer Research
Published
2007-10-01
Volume
67
Issue
19
Pages
9518-9527
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2100519108
Cited by
990
References
57
Citations by year
2026: 30 · 2025: 37 · 2024: 61 · 2023: 86 · 2022: 78 · 2021: 80 · 2020: 93 · 2019: 69 · 2018: 60 · 2017: 58 · 2016: 70 · 2015: 55 · 2014: 64 · 2013: 62 · 2012: 33
FWCI
3.60
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pancreatic Cancer Action Network
  • National Institutes of Health (5f31ai056672-02, C‐A111294, DK050306, CA15704)
  • National Cancer Institute (CA101973, CA84291, CA 15704+, CA111294, U01CA084291, CA114028, R01CA101973, U01CA111294, K08CA114028, P30CA015704)
  • National Institute of Allergy and Infectious Diseases (AI056672)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-050306, P30DK050306)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
pancreatic ductal adenocarcinoma, tumor surveillance, tumor immunology, myeloid-derived suppressor cells, tumor-associated macrophages, regulatory T cells, tumor-infiltrating T cells, pancreatic carcinogenesis, immunosuppression, T cell proliferation inhibition, cancer immunotherapy
MeSH terms
Animals, Leukocytes, Macrophages, Pancreatic Neoplasms, Genes, ras, Lymphocytes, Tumor-Infiltrating, Disease Progression, Carcinoma, Pancreatic Ductal, T-Lymphocytes, Regulatory, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review